Previous 10 | Next 10 |
Ultra-thinly traded nano cap BioCardia ( OTCQB:BCDA ) has rebounded from early pressure on increased volume, albeit on turnover of only 68K shares, in reaction to its public offering of ~1.7M units at $6 per unit. More news on: BioCardia, Inc., Healthcare stocks news, Stocks on the move,...
SAN CARLOS, Calif., Aug. 02, 2019 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 1,666,667 units at a price to the pub...
BioCardia ( OTCQB:BCDA ) inks an extension to its 2017 development agreement with AstraZeneca (NYSE: AZN ) for its Helix biotherapeutic delivery catheter system. More news on: BioCardia, Inc., AstraZeneca PLC, Healthcare stocks news, Read more ...
SAN CARLOS, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZene...
PARIS and SAN CARLOS, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive results from a study of the company’s Helix...
BioCardia ( OTCQB:BCDA ): Q1 GAAP EPS of -$0.08. More news on: BioCardia, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN CARLOS, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2019 and filed...
SAN CARLOS, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the AVANCE™ s...
BioCardia ( OTCQB:BCDA ): Q4 GAAP EPS of -$0.36. More news on: BioCardia, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities and Exchange Co...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therap...
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 ti...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...